A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps

This study has several features that improve the chance of a clean efficacy readout: it is randomized, double-blind, placebo-controlled, multicenter, and uses an objective disease-relevant primary endpoint, change in bilateral endoscopic nasal polyp score at Week 24. That endpoint is less vulnerable to subjective noise than symptom-only measures, and the 24-week treatment window is long enough to detect a meaningful biologic effect if one is present. The enrolled population is also appropriate for showing separation, since participants remain inadequately controlled on intranasal corticosteroids and therefore have room to improve. Offsetting those strengths, this is still a Phase 2 proof-of-concept study, where biological and dose-risk remain substantial. The provided facts do not include prior efficacy data, biomarker enrichment, sample size, or a mechanistic rationale that would justify pushing odds clearly above 50%. Including participants with and without comorbid asthma may also add heterogeneity. Primary completion has passed and status is active-not-recruiting, which supports execution quality, but not necessarily success probability.

Lunsekimig is a bispecific Nanobody blocking both IL-13 and TSLP, both individually validated targets in type 2 inflammation. CRSwNP is a well-proven indication for biologics (dupilumab approved, verekitug showed NPS reduction of -1.77, p<0.0001 in Phase 2). The NPS primary endpoint is regulatory-standard and responsive to anti-inflammatory biologics. Phase 1b data showed lunsekimig was well tolerated with robust pharmacodynamic effects (significant FENO reduction, improved FEV1). Critically, Sanofi has already registered and is actively recruiting a long-term extension study (NCT06914908) for participants completing this parent trial, a strong signal that internal data review was favorable. The trial is 63 days past estimated primary completion with status 'Active Not Recruiting,' consistent with treatment completion. Risks include small sample size (~80 patients), no public efficacy data yet, and notable ADA rates in Phase 1 MAD cohorts (43.8%), though titers were low. Phase 2 PoC base rates (~45%) are tempered upward by the extension study signal and validated mechanism, supporting ~65% probability.

This is a Phase 2 proof-of-concept study for lunsekimig in CRSwNP, an inflammatory condition. Phase 2 POC trials typically have 30-45% success rates. The primary endpoint (change in nasal polyp score at week 24) is objective and clinically meaningful, which is a positive. Sanofi as sponsor provides operational credibility. However, early-stage biologic development in chronic inflammatory diseases carries substantial uncertainty, and proof-of-concept studies often fail to meet statistical significance on primary endpoints. The trial appears to have completed (daysToPrimaryCompletion = -63), suggesting results may be pending. Given the Phase 2 stage and typical POC success rates, intrinsic YES probability is estimated at 40%, below even odds.

This is a Phase 2 PoC study for a new biologic (lunsekimig) in CRSwNP, an area with established biologic pathways. The endpoint (change in bilateral NPS at 24 weeks) is a standard, objective, and clinically meaningful co-primary endpoint in this field. The study design is robust: randomized, double-blind, placebo-controlled, with a 24-week treatment period. Sponsor Sanofi has strong development capabilities. However, this is an early-stage proof-of-concept, and the specific mechanism's efficacy in this population, while plausible, remains unproven. The primary completion date has passed (-63 days), so results are imminent, adding some uncertainty around the specific outcome. The intrinsic probability is modestly above 50% based on solid trial design in a validated therapeutic area.

Well-designed Phase 2 proof-of-concept trial: randomized, double-blind, placebo-controlled, multicenter, with standard CRSwNP population (adults 18-70 inadequately controlled on intranasal corticosteroids, +/- asthma comorbidity). Primary endpoint (change in bilateral NPS from baseline to Week 24) is validated, objective, and sensitive to anti-inflammatory biologics, as shown in prior successes like dupilumab. Sanofi sponsorship implies strong operational execution and data integrity. No prior clinical data on lunsekimig in CRSwNP disclosed; presumed IL-13 targeting aligns with type 2 inflammation pathway but faces high bar in competitive space. Post-primary completion (-63 days), status active not recruiting suggests data lock and analysis underway, low disclosure risk. Phase 2 PoC hit rates for respiratory biologics ~45%, tempered by lack of precedent for this asset: intrinsic YES probability 47%.

This Phase 2 proof-of-concept trial for lunsekimig in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) has a high probability of success. The primary endpoint, change in Nasal Polyp Score (NPS) at Week 24, is a well-validated endpoint historically responsive to IL-4/IL-13 pathway inhibition (e.g., dupilumab). Lunsekimig, a bispecific antibody targeting IL-4Rα and TSLP, offers a mechanistically synergistic approach, building on established efficacy signals from prior monoclonal antibodies in this indication. The trial design is robust: a parallel, randomized, double-blind, placebo-controlled setup in patients inadequately controlled on intranasal corticosteroids provides a clear efficacy signal over standard of care. The inclusion of patients with comorbid asthma broadens the population without confounding the primary nasal endpoint. With an estimated primary completion in January 2026, top-line data is imminent. The sponsor's execution risks appear low given Sanofi's experience. The primary risk is disclosure delay rather than clinical failure.

Sanofi's lunsekimig is a dual IL-4/IL-13 blocker with mechanistic rationale in CRSwNP, where dupilumab (IL-4Rα) and omalizumab have established efficacy. Phase 2 POC design with 24-week NPS endpoint is appropriate and well-powered for signal detection. The primary completion date passed 63 days ago with 'Active Not Recruiting' status suggesting data collection complete and analysis ongoing—typical for Sanofi operational execution. NPS is a validated, regulator-accepted endpoint. Inclusion of asthma comorbidity reflects real-world population without confounding primary readout. No disclosed safety signals or trial discontinuations. Disclosure risk is elevated given primary completion timing, but no public data yet. Prior anti-IL-4/13 class data supports ~60% probability of meeting NPS endpoint versus placebo in inadequately controlled population.

The forecast for lunsekimig in CRSwNP (NCT06454240) resolving YES is exceptionally strong. The drug is a bispecific nanobody targeting IL-13 and TSLP. Both pathways are heavily implicated in Type 2 inflammation and have been extensively validated in CRSwNP. Specifically, dupilumab (which targets IL-4/IL-13 signaling) and tezepelumab (which targets TSLP) have both demonstrated robust, statistically significant reductions in nasal polyp scores (NPS) in late-stage trials. As this Phase 2 trial compares lunsekimig against placebo on the standard NPS endpoint at 24 weeks, the biological efficacy risk is minimal. Furthermore, Sanofi is the sponsor; their deep expertise in executing CRSwNP trials (derived from the dupilumab program) mitigates operational and endpoint-measurement risks. Crucially, recent registry updates show that a long-term extension study (NCT06914908) was updated in March 2026 for patients who completed this parent trial, heavily implying the 24-week parent trial concluded without halting for safety issues. Given the active roll-over of patients and the highly validated dual mechanism of action, the drug is overwhelmingly likely to show a statistically significant benefit over placebo. The standard continuous primary endpoint provides ample statistical power.

The trial is a Phase 2, randomized, double-blind, placebo-controlled study with a clear primary endpoint (Change in bilateral endoscopic nasal polyp score) and a well-defined population (adults with Chronic Rhinosinusitis With Nasal Polyps). The study has a reasonable design and duration, and the intervention (lunsekimig) has a plausible mechanism of action. Although the sample size and detailed results are not provided, the study's positive outcome seems feasible given the indication and primary endpoint. However, uncertainty remains due to the inherent risks in clinical trials, such as patient variability and potential side effects.